北京中医药2026，Vol.45Issue(1)：30-41,12.DOI:10.16025/j.1674-1307.2026.01.007
地榆升白片治疗白细胞减少症的临床综合评价
Clinical comprehensive evaluation of Diyu Shengbai Tablets in the treatment of leukopenia
摘要
Abstract
Objective To explore the multi-dimensional clinical value of Diyu Shengbai Tablets in the treatment of leukopenia,clarify their clinical advantages,and promote rational drug use in clinical practice.Methods This study was conducted based on the Guidelines for the Management of Drug Clinical Comprehensive Evaluation(Trial Version 2021),applying methodologies from clinical medicine,epidemiology,evidence-based medicine,and pharmacoeconomics.Using literature research and questionnaire surveys,a multi-criteria decision analysis(MCDA)model was employed to comprehensively evaluate the"6+1"dimensions of Diyu Shengbai Tablets and reveal their clinical value.Results Safety:Based on toxicological studies,data from the National Adverse Reaction Monitoring Center,literature reports of adverse reactions,pharmacovigilance,and risk management,Diyu Shengbai Tablets were concluded to have high safety.Effectiveness:Systematic review and meta-analysis results showed that,compared with drugs such as Leucogen,Batilol,Vitamin B4,and oxymatrine,Diyu Shengbai Tablets were superior in improving white blood cell counts,reducing the incidence of leukopenia and grade III-IV leukopenia,and increasing the effective rate of white blood cell recovery in tumor radiotherapy and chemotherapy,blood disorders,infectious diseases,mental disorders,endocrine diseases,and pediatric diseases.Cost-effectiveness:Diyu Shengbai Tablets are Class B drugs in the national medical insurance catalog and are more economical than PEG-rhG-CSF,rhG-CSF,or the combination of Leucogen and Batilol.Innovation:Innovations were observed in indications,usage,industrial application,and production processes.Suitability:Questionnaire surveys indicated high suitability for both medical staff and patients.Accessibility:Diyu Shengbai Tablets are priced lower than similar drugs listed in the medical insurance and essential drug catalogs,imposing a small economic burden.They have high hospital coverage,extensive online medical platform availability,sufficient total production capacity,abundant and widely distributed raw medicinal material resources,and good sustainability.Traditional Chinese medicine characteristics:Diyu Shengbai Tablets have a long history of medicinal use and wide application as a commonly used TCM.Ancient texts also record that Sanguisorbae Radix promotes hematopoiesis,highlighting clear TCM characteristics.Conclusion Diyu Shengbai Tablets have high clinical value in the treatment of leukopenia.关键词
地榆升白片/白细胞减少症/临床综合评价/中成药Key words
Diyu Shengbai Tablets/leukopenia/clinical comprehensive evaluation/Chinese patent medicine引用本文复制引用
彭博文,吴洁,陈信义,侯丽,陈晓涵,苌安,田英洁,焦倩..地榆升白片治疗白细胞减少症的临床综合评价[J].北京中医药,2026,45(1):30-41,12.基金项目
国家自然科学基金面上项目(82174200) （82174200）
中国中医科学院科技创新工程重大攻关项目(CI2021A01703) （CI2021A01703）
